Epidemiological study of chronic lymphocytic leukemia (CLL) in the province of Manitoba, Canada

dc.contributor.authorBeiggi, Sara
dc.contributor.examiningcommitteeEvans, Jane (Biochemistry and Medical Genetics) Banerji, Versha (Biochemistry and Medical Genetics) Johnston, James (Internal Medicine) Pitz, Marshall (Internal Medicine) Fritschi, Lin (University of Western Australia)en_US
dc.contributor.supervisorGibson, Spencer (Biochemistry and Medical Genetics) Griffith, Jane (Community Health Sciences)en_US
dc.date.accessioned2014-04-15T18:18:54Z
dc.date.available2014-04-15T18:18:54Z
dc.date.issued2013en_US
dc.degree.disciplineBiochemistry and Medical Geneticsen_US
dc.degree.levelDoctor of Philosophy (Ph.D.)en_US
dc.description.abstractA previous population-based study of survival in Chronic Lymphocytic Leukemia (CLL) patients in the province of Manitoba demonstrated a lower five-year relative survival among CLL patients compared with the age- and gender-adjusted general population. This decreased relative survival was most pronounced among elderly male CLL patients. In this study, we have demonstrated that the reduced five-year relative survival observed in CLL patients compared to the general population of Manitoba may partially be attributed to increased risk of second cancers and non-referral to specialized CLL clinics. The increased risk of second cancers in CLL patients compared to Follicular Lymphoma (FL), a similar indolent B cell malignancy, was only observed after CLL diagnosis indicating that a CLL-specific factor may be responsible for the increased risk of second cancers in these patients. The risk of second cancers is independent of treatment and surveillance bias but is further increased with chemotherapy. A superior outcome in CLL patients who have been referred to the CancerCare Manitoba (CCMB) specialized CLL clinic was observed that was independent of age, gender, treatment and history of previous cancers. This superior outcome was most pronounced in the elderly CLL patients. We propose that CLL patients should be referred to CLL-specific hematologists and, where not possible, that guidelines created by such experts be followed. Appropriate screening for second cancers should be performed during routine follow up of CLL patients.en_US
dc.description.noteOctober 2014en_US
dc.identifier.citationBeiggi S, Johnston JJ, Seftel MD, Pitz MW, Kumar R, Banerji V, et al. Increased risk of second malignancies in Chronic Lymphocytic Leukemia patients as compared with Follicular Lymphoma patients: A Canadian population-based study. Br J Cancer. 2013en_US
dc.identifier.urihttp://hdl.handle.net/1993/23508
dc.language.isoengen_US
dc.publisherBritish Journal of Cancer (Nature Group)en_US
dc.rightsopen accessen_US
dc.subjectEpidemiologyen_US
dc.subjectChronic Lymphocytic Leukemia (CLL)en_US
dc.subjectSmall Lymphocytic Lymphoma (SLL)en_US
dc.subjectFollicular Lymphoma (FL)en_US
dc.subjectNon-Melanoma Skin Cancers (NMSCs)en_US
dc.subjectPopulation-based studyen_US
dc.subjectSecond malignanciesen_US
dc.subjectSpecialized CLL clinicen_US
dc.subjectReferralen_US
dc.subjectOutcomeen_US
dc.titleEpidemiological study of chronic lymphocytic leukemia (CLL) in the province of Manitoba, Canadaen_US
dc.typedoctoral thesisen_US
local.subject.manitobayesen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Beiggi_Sara.pdf
Size:
2.12 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.25 KB
Format:
Item-specific license agreed to upon submission
Description: